Patents by Inventor Steven Shak

Steven Shak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method to Use Gene Expression to Determine Likelihood of Clinical Outcome of Renal Cancer
    Publication number: 20240096451
    Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
    Type: Application
    Filed: August 23, 2023
    Publication date: March 21, 2024
    Applicant: Genomic Health, Inc.
    Inventors: Wayne Cowens, Steven SHAK, Audrey GODDARD, Dejan KNEZEVIC, Joffre Baker, Michael C. Kiefer, Tara MADDALA, Frederick L. Baehner
  • Method to use gene expression to determine likelihood of clinical outcome of renal cancer
    Patent number: 11776664
    Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: October 3, 2023
    Assignee: Genomic Health, Inc.
    Inventors: Wayne Cowens, Steven Shak, Audrey Goddard, Dejan Knezevic, Joffre Baker, Michael C. Kiefer, Tara Maddala, Frederick L. Baehner
  • Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
    Patent number: 11551782
    Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the quantitative score and the gene subsets may be weighted according to their contribution to cancer recurrence.
    Type: Grant
    Filed: November 2, 2020
    Date of Patent: January 10, 2023
    Assignee: Genomic Health, Inc.
    Inventors: Steven Shak, George Andrew Watson, Michael R. Crager, Tara Maddala, Margarita Lopatin, Audrey Goddard, Dejan Knezevic, Christer Svedman
  • METHOD FOR USING GENE EXPRESSION TO DETERMINE PROGNOSIS OF PROSTATE CANCER
    Publication number: 20220396842
    Abstract: The present disclosure includes assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for the patient, and likelihood that the patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status.
    Type: Application
    Filed: August 19, 2022
    Publication date: December 15, 2022
    Inventors: Steven SHAK, Frederick L. Baehner, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER
  • Method to Use Gene Expression to Determine Likelihood of Clinical Outcome of Renal Cancer
    Publication number: 20220051755
    Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
    Type: Application
    Filed: November 19, 2020
    Publication date: February 17, 2022
    Applicant: Genomic Health, Inc.
    Inventors: Wayne COWENS, Steven SHAK, Audrey GODDARD, Dejan KNEZEVIC, Joffre BAKER, Michael C. KIEFER, Tara MADDALA, Frederick L. BAEHNER
  • Gene Expression Profile Algorithm for Calculating a Recurrence Score for a Patient with Kidney Cancer
    Publication number: 20220044760
    Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the quantitative score and the gene subsets may be weighted according to their contribution to cancer recurrence.
    Type: Application
    Filed: November 2, 2020
    Publication date: February 10, 2022
    Applicant: Genomic Health, Inc.
    Inventors: Steven SHAK, George Andrew WATSON, Michael R. CRAGER, Tara MADDALA, Margarita LOPATIN, Audrey GODDARD, Dejan KNEZEVIC, Christer SVEDMAN
  • Gene expression markers for breast cancer prognosis
    Patent number: 11220715
    Abstract: The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: January 11, 2022
    Assignee: Genomic Health, Inc.
    Inventors: Melody A. Cobleigh, Steven Shak, Joffre B. Baker, Maureen T. Cronin
  • Method to Use Gene Expression to Determine Likelihood of Clinical Outcome of Renal Cancer
    Publication number: 20210166790
    Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
    Type: Application
    Filed: November 19, 2020
    Publication date: June 3, 2021
    Applicant: Genomic Health, Inc.
    Inventors: Wayne COWENS, Steven SHAK, Audrey GODDARD, Dejan KNEZEVIC, Joffre BAKER, Michael C. KIEFER, Tara MADDALA, Frederick L. BAEHNER
  • Gene Expression Profile Algorithm for Calculating a Recurrence Score for a Patient with Kidney Cancer
    Publication number: 20210151122
    Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the quantitative score and the gene subsets may be weighted according to their contribution to cancer recurrence.
    Type: Application
    Filed: November 2, 2020
    Publication date: May 20, 2021
    Applicant: Genomic Health, Inc.
    Inventors: Steven SHAK, George Andrew WATSON, Michael R. CRAGER, Tara MADDALA, Margarita LOPATIN, Audrey GODDARD, Dejan KNEZEVIC, Christer SVEDMAN
  • Gene expression profile algorithm and test for determining prognosis of prostate cancer
    Patent number: 11011252
    Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: May 18, 2021
    Assignee: Genomic Health, Inc.
    Inventors: Steven Shak, Mark Lee, William F. Novotny, Tara Maddala, Michael R. Crager, Diana Cherbavaz, Robert J. Pelham, Carl L. Millward, Dejan Knezevic
  • Method to use gene expression to determine likelihood of clinical outcome of renal cancer
    Patent number: 10892038
    Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: January 12, 2021
    Assignee: Genomic Health, Inc.
    Inventors: Wayne Cowens, Steven Shak, Audrey Goddard, Dejan Knezevic, Joffre Baker, Michael C. Kiefer, Tara Maddala, Frederick L. Baehner
  • Prediction of Likelihood of Cancer Recurrence
    Publication number: 20200299781
    Abstract: The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.
    Type: Application
    Filed: March 3, 2020
    Publication date: September 24, 2020
    Applicant: Genomic Health, Inc.
    Inventors: Joffre B. Baker, John L. Bryant, Soonmyung Paik, Steven Shak
  • Method for Using Gene Expression to Determine Prognosis of Prostate Cancer
    Publication number: 20200255911
    Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
    Type: Application
    Filed: February 25, 2020
    Publication date: August 13, 2020
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Steven SHAK, Frederick L. BAEHNER, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER
  • Prediction of likelihood of cancer recurrence
    Patent number: 10619215
    Abstract: The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: April 14, 2020
    Assignee: Genomic Health, Inc.
    Inventors: Joffre B. Baker, John L. Bryant, Soonmyung Paik, Steven Shak
  • Method for Using Gene Expression to Determine Prognosis of Prostate Cancer
    Publication number: 20190249260
    Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
    Type: Application
    Filed: February 22, 2019
    Publication date: August 15, 2019
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Steven SHAK, Frederick L. BAEHNER, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER
  • TREATMENT WITH ANTI ErbB2 ANTIBODIES
    Publication number: 20190240185
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient.
    Type: Application
    Filed: April 23, 2019
    Publication date: August 8, 2019
    Applicant: Genentech, Inc.
    Inventors: Susan Desmond-Hellmann, Virginia Paton, Steven Shak
  • Treatment with anti-ErbB2 antibodies
    Patent number: 10280228
    Abstract: The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: May 7, 2019
    Assignee: Genentech, Inc.
    Inventors: Sharon A. Baughman, Steven Shak
  • Method for using gene expression to determine prognosis of prostate cancer
    Patent number: 10260104
    Abstract: The present disclosure includes assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for the patient, and likelihood that the patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: April 16, 2019
    Assignee: Genomic Health, Inc.
    Inventors: Steven Shak, Frederick L. Baehner, Tara Maddala, Mark Lee, Robert J. Pelham, Wayne Cowens, Diana Cherbavaz, Michael C. Kiefer, Michael Crager, Audrey Goddard, Joffre B. Baker
  • Gene Expression Profile Algorithm for Calculating a Recurrence Score for a Patient with Kidney Cancer
    Publication number: 20190095575
    Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the quantitative score and the gene subsets may be weighted according to their contribution to cancer recurrence.
    Type: Application
    Filed: November 26, 2018
    Publication date: March 28, 2019
    Applicant: Genomic Health, Inc.
    Inventors: Steven SHAK, George Andrew WATSON, Michael R. CRAGER, Tara MADDALA, Margarita LOPATIN, Audrey GODDARD, Dejan KNEZEVIC, Christer SVEDMAN
  • TREATMENT WITH ANTI-ErbB2 ANTIBODIES
    Publication number: 20190071516
    Abstract: The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody.
    Type: Application
    Filed: November 12, 2018
    Publication date: March 7, 2019
    Applicant: Genentech, Inc.
    Inventors: Sharon A. Baughman, Steven Shak